<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833869</url>
  </required_header>
  <id_info>
    <org_study_id>0020-19-WOMC</org_study_id>
    <nct_id>NCT03833869</nct_id>
  </id_info>
  <brief_title>Assisted Hatching in Frozen Blastocysts</brief_title>
  <official_title>The Effect of Assisted Hatching on Implantation Rate in Frozen Blastocyst Transfer - a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aims to assess the effect of assisted hatching on the implantation rate of
      frozen blastocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Zona Pellucida protects the ovum from the penetration of multiple sperm, and from
      mechanical and physiological damage until the fertilized ovum reaches the uterus.
      Subsequently, spontaneous hatching occurs, and enables the embryo to attach to the
      endometrium. The technique of assisted hatching was originally investigated as a means to
      improve implantation in cases of zona hardening, and is commonly performed in 3-day embryos.
      In the current study, the investigators aim to investigate the effect of assisted hatching on
      5-day frozen embryos.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>Five to six weeks following embryo transfer</time_frame>
    <description>Number of gestational sacs demonstrated on ultrasound divided by the number of embryos transferred (expressed as percentage)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy</measure>
    <time_frame>Five to six weeks following embryo transfer</time_frame>
    <description>Increase and subsequent decrease in beta HCG levels with no evidence of gestational sac on ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early spontaneous abortion</measure>
    <time_frame>Up to 15 weeks from embryo transfer</time_frame>
    <description>Spontaneous abortion of pregnancy during the first trimester of pregnancy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>ART</condition>
  <arm_group>
    <arm_group_label>Assisted hatching</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five-day frozen embryos will undergo assisted hatching prior to embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Five-day frozen embryos will not undergo any additional procedures prior to embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Assisted hatching</intervention_name>
    <description>Controlled hatching of the zona pellucida in the laboratory prior to embryo transfer</description>
    <arm_group_label>Assisted hatching</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In-vitro fertilization patients at the investigators' institution, intended to undergo
             a transfer of a frozen five-day embryo (blastocyte)

          -  18 to 39 years old

          -  First to third treatment cycle

          -  Patient has previously had a maximum of four embryos transferred.

        Exclusion Criteria:

          -  Over 40 years old

          -  Congenital or acquired uterine malformations

          -  Hydrosalpinx

          -  Chronic autoimmune diseases

          -  Embryo intended to be undergo preimplantation genetic diagnosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadas Ganer Herman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Edith Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadas Ganer Herman, MD</last_name>
    <phone>9720526206696</phone>
    <email>hadassganer@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Edith Wolfson Medical Center</name>
      <address>
        <city>HÌ±olon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hadas Ganer Herman, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wolfson Medical Center</investigator_affiliation>
    <investigator_full_name>Hadas Ganer Herman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

